Ameriprise
PALI icon

Ameriprise’s Palisade Bio PALI Stock Holding History

Ameriprise’s Portfolio PALI Stock Details PALI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.2M Sell
11,081,434
-428,886
-4% -$844K ﹤0.01% 1435
2026
Q1 		$20.1M Buy
11,510,320
+4,599,083
+67% +$8.36M ﹤0.01% 1405
2025
Q4 		$16.2M Buy
+6,911,237
New +$13.3M ﹤0.01% 1566

Other funds holding PALI

SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Ameriprise's PALI Position: Q2 2026 in Review

Ameriprise reduced its Palisade Bio (PALI) stake by 3.7% in Q2 2026, selling an estimated $844K and leaving 11,081,434 shares worth $23.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1435.

Ameriprise first reported a position in PALI in Q4 2025 and has held it in 3 quarters since. 124 funds tracked by Wall St. Rank hold PALI as of Q2 2026.

  • Ameriprise held 11,081,434 shares of Palisade Bio worth $23.2M as of Q2 2026.
  • Ameriprise sold 428,886 Palisade Bio shares in Q2 2026, an estimated $844K.
  • Palisade Bio made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #1435 holding.
  • Ameriprise first reported a position in Palisade Bio in Q4 2025 and has held it in 3 quarters since.
  • 124 funds tracked by Wall St. Rank held Palisade Bio as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.